Hims Hers Health Inc (HIMS) | 180D | Tradepal - AI Trading Software with Real-Time Signals

Hims Hers Health Inc (HIMS)|180d

Modal Stance

bearish

Probability Score

Forecast Chart

Base Target

Bull Target

Bear Target

Pivot$38.19

Resistance Level (R1)$55.26

Support Level (S1)$5.95

Chance of breaking S1 in 72h: 22%

Why the Model thinks this

Bull Case:N/ABase Case:N/ABear Case:N/A

Analyst Ratings

64.7%of 17 ratings

Buy

64.70%

Hold

29.40%

Sell

5.90%

Source(s): MarketBeat | TipRanks | Yahoo Finance | Zacks Investment Research

Drivers of Forecast

News & Sentiment

-0.75 (Negative)

The U.S. Department of Health and Human Services has referred Hims & Hers to the DOJ for investigation regarding potential violations of federal drug laws.
Hims & Hers officially dropped plans for its $49 compounded weight-loss pill only two days after launch following FDA and legal pushback.
The FDA signaled 'swift action' to restrict active pharmaceutical ingredients used in non-approved compounded GLP-1 medications, striking Hims' growth engine.
Bank of America maintains an 'Underperform' rating with a reduced price target of $29, citing consensus expectations that may be too high.
The company is diversifying revenue streams by launching access to GRAIL’s Galleri multi-cancer early detection blood test on its platform.
Amazon Pharmacy’s move to offer branded Wegovy directly to consumers creates a significant competitive headwind for Hims' telehealth subscription model.
Hims & Hers is scheduled to report its Q4 and full-year 2025 financial results on February 23, 2026, which will be a critical catalyst for the stock.

Technical Indicators

MA (50)

$33.3

MACD

Bullish

RSI (14)

36.98

Volume

+116% above avg

*Watch for short below $5.95 support breakdown

Analysis Date

Feb 09, 2026 | 10:59 AM

Signals & Anomalies

Extreme Volatility Expansion and Volume SurgeTrading volume peaked at 244.7M shares on the 18th day of the sequence, representing nearly 2x the 20-day average. This massive volume accompanied a price swing from 65.59 high to 50.22 low, signaling significant institutional liquidation and high-stakes volatility following the DOJ referral news.
Bearish Price Gapping with Resistance TestingThe stock collapsed from an intraday high of 70.43 on day 19 down to 57.65 on day 20. This downward movement broke through several psychological support levels in quick succession, turning former $60+ highs into heavy overhead resistance area for future recovery attempts.
High Frequency CDLENGULFING Pattern SignalCDLENGULFING patterns were detected 5 times with an 80% historical success rate in the technical summary. Given the recent extreme daily ranges (e.g., day 18 spread of $15.37), these engulfing patterns indicate aggressive dominance by sellers during intraday reversals.
Rapid Mean Reversion after PeakAfter hitting a peak adj_close of 62.55 on day 19, the price retraced to 57.65 on day 20. This 7.8% drop occurred alongside sustained high volume, confirming that the speculative momentum driven by the semaglutide launch has been fully neutralized by regulatory and legal headwinds.

Market Regimebearish

Upcoming Catalysts